Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

NCT06561152 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Refractory Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia

Interventions

DRUG: Tagraxofusp
DRUG: Cladribine (CLAD)
DRUG: Cytarabine

Sponsor

Stanford University

Collaborators

[object Object]